Design of a Sensitive Fluorescent Zn-Based Metal-Organic Framework Sensor for Cimetidine Monitoring in Biological and Pharmaceutical Samples

A new highly fluorescent zinc-organic framework [Zn₂(btca)(DMSO)₂]_n (Zn-MOF) was prepared via in situ ligand formation by the solvothermal reaction of Zn(NO₃)₂·6H₂O and pyromellitic dianhydride (PMDA) in DMSO solvent. During the solvothermal reaction, PMDA was gradually hydrolyzed to a pyromellitic acid, 1,2,4,5-benzene tetracarboxylic acid (H₄btca), to provide a tetracarboxylic acid as a linker in the reaction medium. Single-crystal X-ray diffraction analysis exhibits a 3D porous structure with open tetragonal channels running along the crystallographic c-axis. The Zn-MOF was explored as an on-mode fluorescent sensor for tracing cimetidine in biological fluids and pharmaceutical samples in the presence of interfering species. The results show a quick response in a short time range. The characteristics of this sensor were investigated by field-emission scanning electron microscopy, dynamic light scattering, energy-dispersive X-ray analysis, powder X-ray diffraction, Fourier transform infrared and UV-vis spectroscopy as well as thermogravimetric, and elemental analyses.

A novel stability-indicating method for known and unknown impurities profiling for diltiazem hydrochloride pharmaceutical dosage form (tablets)

Background

A novel gradient, high-sensitive and specific stability-indicating reverse-phase HPLC method was developed and validated for quantitative purpose of known, unknown and degradant impurities profiling for diltiazem hydrochloride tablets. The impurities were separated on the Zorbax RX C8 column (150 mm × 4.6 mm, 5 μm) with mobile phase-A consisting of a mixture of 0.05 M sodium dihydrogen phosphate monohydrate buffer pH 3.0 and methanol in the ratio 800:200v/v and mobile phase-B consisting of acetonitrile with a flow rate of 1.0 mL min−1. The column compartment was maintained at 35 °C, and the detection wavelength was 240 nm. Diltiazem hydrochloride, its known impurities and unknown impurities have been well resolved from each other.

Results

The linearity of the method has been demonstrated across the concentration range of 0.18 to 5.65 µg mL−1 for EP impurity-F with correlation coefficient R2 greater than 0.99. Recovery of method was proved from LOQ to 150% for known and unknown impurities with respect to test concentration and found in between 80 and 120%. Forced degradation study and specificity experiment results with mass balance proved the stability-indicating nature of the method and separated all known, unknown impurities and degradants from each other as well as from main drug component (diltiazem hydrochloride). The mass balance for stress study was found in between 95 and 105%.

Conclusion

Newly developed analytical method was validated as per ICH Q2 (R1) guidelines “Validation of analytical procedure” and found linear, accurate, specific, robust and precise in the established working range.

Novel flow injection spectrophotometric determination of ranitidine in pharmaceuticals

A novel flow injection spectrophotometric determination of ranitidine in pharmaceuticals is reported. The method is based on a compound formed in a reaction using ranitidine with and potassium permanganate in neutral media, which can be monitored at 430 nm. Under optimal conditions, an analytical curve was constructed, which was linear in the range between 5.0 × 10−5 and 1.0 × 10−3 mol L−1 with a detection limit of 1.0 × 10−5 mol L−1. In addition, the sample throughput was 60 h−1 and the obtained results for commercial formulation samples by applying the proposed method were in good agreement with labeled values and those obtained by a reference method at a 95% confidence level.